Retarding neutrophil infiltration ad morphologic reduction in ischemic bowel tissues
US5801198A · kind A · utility
2Cited by
13References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 13, 1995 |
| Grant date | Sep 1, 1998 |
| Priority date | — |
| Expiry date | Jul 13, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Treating mammals having ischemic bowel with a therapeutic quantity of pyruvate enterally or parenterally will retard neutrophil infiltration and retain morphology during and following the bowel ischemia. The pyruvate is introduced into the patient enterally or parenterally during the bowel ischemia or the succeeding bowel reperfusion and, preferably, prior to the bowel ischemia. The pyruvate dosage is from 1% to 20% by weight of the patient's caloric intake.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.